Close Menu

private financing

The funding adds to a $121 million raise the company announced last month and will go towards expanding and commercializing its SomaScan platform.

The company offers a blood test that detects human papillomavirus-related cancer by measuring tumor tissue-modified viral DNA using droplet digital PCR.

The company is developing a liquid biopsy technology that uses circulating tumor DNA methylation signatures for the early detection of cancer.

The company said that it plans to use the funds for facilities and equipment needed to scale up operation of its KScan phosphoproteomic platform.

The firm is placing systems with at least two research collaborators and plans to target six to 10 early-access customers for its ProteoGraph platform in 2021.

The Germany-based company is developing Molecular Cartography, a technology that offers multiplexed analysis of gene expression in tissues.

The Stanford University spinout cofounded by Euan Ashley will use the funding to develop its microfluidics-based cell sorting and analysis technology.

The company, which raised about $1.6 million earlier this year, said it will use the new funding to accelerate development of its 3D sequencing platform.

The company plans to use proceeds from the round to further commercialize products based on its mass spec multinozzle emitter array (MEA) technology.

The company said it will use proceeds from the round, which was led by Casdin Capital, to expand and commercialize its SomaScan platform and SomaSignal tests.


NPR reports that researchers have developed chimeric embryos as part of work toward growing human organs in animals for organ transplants.

According to the Washington Post, the Biden Administration is set to make changes to federal restrictions on fetal tissue research.

In Science this week: approach to isolated trace DNA from archaic humans from sediments, and more.

Texas Monthly looks into the DNA Zoo being collected by Baylor College of Medicine researchers.